Bioo Scientific awarded two SBIR grants to enable the improvement of single cell sequencing technologies

Bioo Scientific is developing tools which will allow researchers to study dynamic variation in epigenomics from a single cell. Until now, single-cell analysis of DNA methylation has proven itself to be technically challenging and there are no kits commercially available which can facilitate this analysis. Bioo Scientific was recently awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) to develop innovative solutions to improve single cell sequencing.

The first grant, Sequencing of Epigenetic Modifications from Single Cells, will be used to further the development of single-cell methylome sequencing for use in in a number of applications, including epigenome analysis of heterogeneous organs and research on epigenetic drug resistance.

The second grant, DGE Analysis by 3’ End Sequencing, will allow researchers to sequence the 3’ end of RNA molecules. Existing 3’ end sequencing protocols have revealed that most eukaryotic genes display alternative cleavage and polyadenylation (APA), where RNA isoforms using different cleavage and polyadenylation sites (pAs) can be generated from the same gene. Importantly, these different isoforms have been shown to be metabolized differently, including variations in stability, localization, and translation. With this grant, Bioo Scientific will develop a new tool that completely addresses false priming and incomplete 3′ end annotation, significantly advancing research on single cell RNA expression.

The kits Bioo Scientific will develop with this funding have the potential to have a positive impact on both basic research and clinical analysis in the future.

About Bioo Scientific Corporation

Bioo Scientific is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products that increase the sensitivity, flexibility and speed of next-generation sequencing.

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.